Trial Profile
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Acronyms CHRONOS-3
- Sponsors Bayer; Bayer HealthCare
- 04 Feb 2024 This trial has been discontinued in Italy.
- 16 Jan 2024 Results deriving data from copanlisib exposure-efficacy relationships from this study for developing Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen, published in the Clinical Pharmacology and Therapeutics
- 22 Dec 2023 This trial has been Completed in Greece, according to the European Clinical Trials Database record.